• AZ505: Potent and Selective SMYD2 Inhibitor for Epigeneti...

  2026-01-07

  AZ505, a potent and selective SMYD2 inhibitor supplied by APExBIO, empowers researchers to probe the histone methylation pathway with unmatched specificity. Its substrate-competitive mechanism, high selectivity, and robust data-driven performance make it a go-to tool for advancing epigenetic regulation research across oncology, renal fibrosis, and disease modeling.

• Optimizing High-Throughput Oncology: Practical Insights w...

  2026-01-06

  This article provides scenario-driven, evidence-based guidance for biomedical researchers and lab technicians seeking robust solutions for cancer drug discovery. Leveraging the L1023 Anti-Cancer Compound Library (SKU L1023), we address common experimental challenges, from assay inconsistency to compound selection, with actionable best practices and peer-reviewed data. Discover how SKU L1023 enables reproducible, high-sensitivity anti-cancer screening workflows.

• L1023 Anti-Cancer Compound Library: High-Throughput Scree...

  2026-01-05

  The L1023 Anti-Cancer Compound Library enables high-throughput screening of anti-cancer agents and molecular target discovery in oncology research. This resource is optimized for cell-permeable compounds and includes inhibitors of key pathways such as BRAF kinase, EZH2, mTOR, and HDAC6. By leveraging this library, researchers can accelerate drug discovery and pathway deconvolution in cancer biology.

• Tetrandrine Alkaloid: Reliable Calcium Channel Blocker fo...

  2026-01-04

  This in-depth guide explores real-lab scenarios where Tetrandrine (SKU N1798) delivers reproducible results in calcium channel modulation, cell viability, and cytotoxicity assays. Drawing on practical Q&A and evidence-based discussion, it demonstrates how this neuroscience research compound streamlines workflows and enhances data integrity for biomedical researchers.

• AZ505: Next-Generation SMYD2 Inhibition in Epigenetic and...

  2026-01-03

  Explore how AZ505, a potent and selective SMYD2 inhibitor, is redefining the study of protein lysine methyltransferase inhibition and epigenetic regulation research. This article uncovers advanced mechanistic insights and emerging therapeutic implications, providing researchers with a deeper perspective on the histone methylation pathway.

• AZ505 and the Epigenetic Frontier: Unveiling SMYD2 Inhibi...

  2026-01-02

  Explore the unique advantages of AZ505, a potent and selective SMYD2 inhibitor, in dissecting the histone methylation pathway for advanced cancer and fibrosis research. Discover mechanistic insights and differentiated applications not found in other resources.

• DiscoveryProbe™ Protease Inhibitor Library: High-Content ...

  2026-01-01

  The DiscoveryProbe Protease Inhibitor Library (SKU: L1035) is a validated, automation-ready protease inhibitor library for high throughput screening. It provides 825 cell-permeable, stable inhibitors targeting all major protease families, supporting robust protease activity modulation in apoptosis, cancer, and infectious disease research.

• AZ505 and the Future of SMYD2 Inhibition: Strategic Insig...

  2025-12-31

  As the complexity of disease models deepens, the precise regulation of epigenetic mechanisms like histone methylation is at the forefront of translational research innovation. This article explores the mechanistic rationale and strategic applications of AZ505, a potent and selective SMYD2 inhibitor, with a focus on its substrate-competitive inhibition, high selectivity, and emerging roles in cancer biology, fibrosis, and beyond. By integrating recent experimental findings and workflow guidance, we provide translational researchers with actionable insights for leveraging AZ505 in next-generation biomedical discovery.

• L1023 Anti-Cancer Compound Library: Precision Profiling f...

  2025-12-30

  Explore how the L1023 Anti-Cancer Compound Library empowers drug discovery through advanced profiling of cell-permeable anti-cancer compounds. This in-depth analysis reveals unique strategies for targeting novel pathways and biomarkers in cancer research.

• DiscoveryProbe Protease Inhibitor Library: Transforming H...

  2025-12-29

  The DiscoveryProbe™ Protease Inhibitor Library redefines high throughput and high content screening with its extensive, validated collection of cell-permeable inhibitors. Researchers gain a decisive edge in apoptosis, cancer, and infectious disease studies through robust automation compatibility, diverse mechanistic coverage, and actionable troubleshooting support.

• L1023 Anti-Cancer Compound Library: Systems Oncology and ...

  2025-12-28

  Explore how the L1023 Anti-Cancer Compound Library accelerates drug discovery in cancer research. This in-depth article uncovers a systems-level approach to biomarker targeting and pathway interrogation, offering deeper scientific insights and advanced applications.

• Tetrandrine (SKU N1798): Solving Lab Challenges in Cell A...

  2025-12-27

  This article dissects real-world laboratory hurdles—such as assay reproducibility, solubility bottlenecks, and data interpretation—in cell viability and signaling research. Using scenario-driven Q&A, it demonstrates how Tetrandrine (SKU N1798), a high-purity calcium channel blocker for research from APExBIO, delivers data-backed solutions. Researchers will find actionable insights for optimizing protocols, ensuring experimental fidelity, and selecting reliable reagents.

• L1023 Anti-Cancer Compound Library: Precision Tools for N...

  2025-12-26

  Explore the L1023 Anti-Cancer Compound Library—a cell-permeable anti-cancer compound library for drug discovery—through the lens of precision target identification and advanced pathway interrogation. Discover how its unique blend of potent inhibitors and curated design enables translational breakthroughs beyond standard high-throughput screening.

• Tetrandrine Alkaloid: Precision Calcium Channel Blocker f...

  2025-12-25

  Tetrandrine alkaloid from APExBIO enables reproducible, high-fidelity neuroscience, cancer biology, and ion channel modulation studies. Its robust solubility and validated bioactivity make it a benchmark calcium channel blocker for research, empowering advanced applications and troubleshooting.

• L1023 Anti-Cancer Compound Library: Structure-Guided Solu...

  2025-12-24

  The L1023 Anti-Cancer Compound Library offers a curated set of 1,164 cell-permeable compounds for high-throughput screening of anti-cancer agents. As an optimized anti-cancer compound library for drug discovery, it enables systematic evaluation of key oncogenic pathways including BRAF, EZH2, mTOR, and more. APExBIO’s L1023 supports reproducible, target-focused cancer research with robust, published evidence of compound potency and selectivity.

14996 records 1/1000 page Next 12345 下5页 Last page